Allogeneic hematopoietic stem cell transplantation (HSCT)-related membranous glomerulonephritis (MGN) is poorly understood. A total of 830 patients who underwent HSCT at Toranomon Hospital from 2000 to 2012 were evaluated retrospectively, including 621 patients receiving umbilical cord blood transplantation (UCBT) and 208 patients receiving unrelated bone marrow transplantation. MGN was diagnosed in 5 patients after UCBT (versus none after bone marrow transplantation) and occurred concomitantly with chronic graft-versus-host disease after cessation of immunosuppression. Light microscopy did not show any definite spikes or bubbling of the glomerular basement membrane (GBM) in all 5 patients. In 1 patient (case 5), endocapillary proliferative lesions with fibrin-like deposits were noted in addition to MGN findings. Immunofluorescence demonstrated granular deposits of immunoglobulin G (IgG; IgG1 and IgG4) along the GBM with negativity for C3, C4, and C1q in 4 patients (cases 1-4), whereas case 5 showed positivity for IgG (IgG1, IgG2, IgG3, and IgG4) as well as for C3, C4, and C1q. Electron microscopy revealed electron-dense deposits in the subepithelial space of the GBM in cases 1-4. In case 5, electron-dense deposits were present in the mesangium and the subendothelial space of the GBM, as well as in the subepithelial space. After treatment with immunosuppressants (prednisolone and/or cyclosporin) or angiotensin-converting enzyme inhibitors, complete remission with disappearance of proteinuria was achieved 12.2 months in all 5 patients, but ☆ Competing interest: All authors report no conflicts of interest. ☆☆ Consent: These patients have given their consent for the case report to be published. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Human Pathology (2016) 50, 187-194 nephrotic-range proteinuria relapsed in 2 patients during follow-up. Serum anti-PLA2R autoantibody was negative in 3 patients. HSCT-related MGN only occurred after UCBT. We believe that there were 2 morphologic patterns: early MGN and membranoproliferative pattern glomerulonephritis.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a common treatment of a variety of hematopoietic malignancies. Chronic kidney disease develops in 15% to 20% of recipients at several months after HSCT and is considered due to chronic calcineurin inhibitor nephrotoxicity, HSCT-associated thrombotic microangiopathy (TMA), and glomerular diseases including membranous glomerulonephritis (MGN), minimal change disease (MCD), membranoproliferative glomerulonephritis, and focal segmental glomerulosclerosis [1] . Brukamp et al [2] found that MGN accounted for almost two-thirds of nephrotic syndrome after HSCT, followed by MCD in nearly one quarter of patients. MGN occurs in synchronization with manifestation of chronic graft-versus-host disease (CGVHD) such as skin lesions shortly after the cessation of immunosuppressive therapy, so MGN after HSCT is considered secondary to CGVHD.
On the other hand, idiopathic MGN is the main cause of nephrotic syndrome in adults and is characterized by accumulation of immune complexes in the glomerular basement membrane (GBM). The immunoglobulin (Ig) G deposits in the glomeruli are predominantly composed of IgG4. Recently, the M-type phospholipase A2 receptor (PLA2R) in podocytes was proposed as the major target antigen involved in adult idiopathic MGN [3, 4] .
Detailed evaluation of post-HSCT MGN by a combination of 3 microscopic techniques (light microscopy [LM], electron microscopy [EM], and immunofluorescence [IF] studies including IgG subclass analysis) has not been done before. Accordingly, we performed a detailed clinicopathological investigation of 5 patients with post-HSCT MGN. We also evaluated the association with anti-PLA2R autoantibody in 3 patients.
Materials and methods

Patient selection
At Toranomon Hospital, HSCT using umbilical cord blood (UCBT) was performed in 621 patients from 2000 to 2012, while HSCT using unrelated bone marrow (BMT) was done in 208 patients. Renal biopsy was performed for evaluation of renal pathology in 20 patients with proteinuria at least 0.3 g daily. These patients were divided into group 1 (11 patients after UCBT) and group 2 (9 patients after BMT). In group 1, the renal histology was MGN in 5 patients, acute tubular necrosis in 2, diabetic nephropathy in 2, TMA in 1, and nephrosclerosis in 1. In group 2, renal histology was acute tubular necrosis in 6 patients, TMA in 2, and MCD in 1.
The 5 patients with MGN from group 1 were analyzed retrospectively. None of them had any of the common causes of secondary MGN, such as malignancy, autoimmune disease such as lupus erythematosus, or hepatitis C and B virus infection.
This study was approved by the local institutional review board, and the patients signed a full informed consent.
Histologic evaluation
Renal biopsy specimens were processed for LM, IF microscopy, and EM according to the previous method [5] . IFs were performed for IgG, IgA, IgM, and IgG subclasses (IgG1-IgG4), as well as antibodies for complement component (C)1q, C3, and C4.
Laboratory tests
Before renal biopsy, blood and urine samples were collected from all patients. Laboratory tests were performed to measure the hemoglobin, white blood cell count, platelet count, serum creatinine, IgG, IgA, IgM, cryoglobulin, antinuclear antibody (including anti-double-stranded DNA antibody and anti-U1-nuclear ribonucleoprotein antibody), 50% hemolytic complement (reference range, 32-47 U/mL), and the estimated glomerular filtration rate (in mL/min per 1.73 m 2 ). Serum hepatitis C virus antibody was evaluated by enzyme-linked immunosorbent assay (Abbott Diagnostics, Maidenhead, UK), and hepatitis B virus antibody was detected with another commercially available enzyme-linked immunosorbent assay kit. Assessment of 24-hour urinary protein excretion was performed, and the urine sediment was examined, including the number of erythrocytes per high-power field. Serum monoclonal protein and urinary Bence-Jones protein were analyzed by protein electrophoresis and/or immunofixation electrophoresis. Serum anti-PLA2R autoantibody was measured in 3 of the 5 patients (patients 1, 4, and 5) according to the previously reported method [4] .
Statistical analysis
Statistical analysis was performed using the χ 2 test.
Quantitative values were expressed as the mean ± SD, and differences were compared by Wilcoxon rank-sum test. A probability (P) value less than .05 was considered to indicate statistical significance. The SPSS software package (SPSS 11.0 for Windows; SPSS, Chicago, IL) was used for all analyses.
Results
Renal first biopsy findings
LM did not show any definite spike formation or bubbling ( Fig. 1A) of the GBM in all 5 patients, but endocapillary proliferative lesions with fibrin-like deposits were noted in glomeruli from case 5 ( Fig. 2A-C) . IF demonstrated granular deposition of IgG along the GBM in all 5 patients ( Fig. 1D ), whereas IgG was also seen in the mesangial region in case 5 (Fig. 2D ). In cases 1 to 4, IgG1 and IgG4 were equally positive. In case 5, there was positivity of IgG1, IgG2, IgG3, and IgG4 (Fig. 2D ). Although C3, C4, and C1q were negative in cases 1 to 4 ( Fig. 1D ), these complement components were positive in case 5 (Fig. 2D ). EM showed subepithelial electron-dense deposits (EDDs) in the GBM (Fig. 1E ) of all 5 cases. In case 5, EDDs were also mainly located in the subepithelial space of the GBM, but were partially in the mesangial region and the subendothelial space ( Fig. 2E ). The subepithelial EDDs were stage 1 without spike-like protrusions arising from the basement membrane. EDDs were very small and segmental in cases 1, 2, and 4, whereas EDDs were larger and more extensive in cases 3 and 5. There were 2 morphologic patterns: early MGN (in cases 1-4) and membranoproliferative pattern glomerulonephritis (in case 5; Table 1 ).
Renal second biopsy findings
In cases 3 and 4, a second renal biopsy was performed after recurrence of nephrotic-range proteinuria. LM revealed definite spikes or bubbling of the GBM (Fig. 1B and  C) . EM demonstrated a mixture of stage 1 to stage III subepithelial deposits without (new) or with (old) spike (Fig. 1F ).
Patient characteristics
The primary malignant disease that was the indication for HSCT was different in each patient, being non-Hodgkin lymphoma, myelodysplastic syndrome, acute lymphoblastic leukemia, plasmacytic lymphoma, and diffuse large B-cell lymphoma. The conditioning regimen (for the purpose of eradicating the malignancy prior to HSCT and suppressing immune reactions) was a combination of total bone irradiation (n = 4, 2-8 Gy) and chemotherapy with fludarabine (n = 5) and busulfan (n = 2) or melphalan (n = 3). CGVHD occurred in the skin, eye, liver, bowel, and nervous system. The time from HSCT to the onset of CGVHD was 7 to 19 months, whereas the time from CGVHD onset to the occurrence of MGN was 2 to 15 months ( Table 2 ).
Laboratory data at the onset of MGN
Serum creatinine was 0.8 to 1.3 mg/dL, estimated glomerular filtration rate was 45 to 89 mL/min per 1.73 m 2 , and urinary protein was 5.93 to 13.0 g/d (mean, 8.4 g/d). Fifty percent hemolytic complement was normal with 42 to 51 U/mL in 3 patients, but was not measured in the other 2 patients. Serum anti-PLA2R autoantibody was negative in 3 patients, but was not tested in the other 2 patients (Table 3) . Ultrasonography did not show any finding suggesting renal vein thrombosis on 5 patients.
Treatment and long-term outcome
The mean observation period after the onset of MN was 92.4 months (range, 38-144 months). Initial treatment of MGN was only an angiotensin-converting enzyme inhibitor in 1 patient, whereas the other 4 patients received prednisolone (PSL; 0.6-0.8 mg/kg/d) and/or cyclosporin (CyA; 50-75 mg/d). All patients achieved complete remission (CR) with disappearance of proteinuria after treatment for a mean of 12.2 months (5-24 months). However, nephrotic-range proteinuria recurred in 2 patients (cases 3 and 4) during follow-up. Cases 3 and 4 also had coexisting extrarenal symptoms of GVHD (bronchiolitis or skin lesion). Treatment was started with PSL (35 mg daily) and CyA (50 mg daily), and proteinuria subsided after 2 months. In case 4, there was also recurrence of nephrotic-range proteinuria (9.8 g daily). Because proteinuria persisted despite administration of PSL (50 mg daily) and CyA (50 mg daily), hemodialysis was started for end-stage renal failure at 73 months after HSCT (Table 4 ).
Discussion
When Otani et al [6] reviewed previous reports, they found that HSCT-related MGN has a pattern resembling secondary MGN, because immune complex deposits are mainly localized in the subepithelium of the GBM, and mesangial deposits are also found in some patients. Similar symptoms and renal histologic changes have been reported in a murine model of GVHD. Chang et al [7] reported 3 cases of HSCT-related MGN consistent with the early stage of MGN or with atypical MGN. In addition, Chan et al reported 4 cases of MGN. The glomerular capillary walls displayed varying stages of remodeling. Two patients were diagnosed as having atypical MGN showing a few mesangial EDDs [8] . Furthermore, Reddy et al [9] reported 5 cases of HSCT-related MGN showing a mixture of stages 1 to 3 with diffuse thickening of the GBM and that deposits exist on both subepithelial and intramembranous sites. Terrier et al [10] also reported 5 MGN patients. Renal biopsy showed early stage of MGN. IgG1 was positive in 5 patients. EM findings were not shown.
The mechanism underlying the development of MGN after HSCT remains unclear. Many patients with MGN have active CGVHD at the diagnosis of MGN. Close relation between CGVHD and MGN is suggested [10] . GVHD is primarily a T-cell-mediated disease, in which donor T cells recognize major histocompatibility complex mismatch, as well as targeting other host antigens [11] . A recent report suggested that B cells also contribute to GVHD thorough both antibody-dependent and antibody-independent mechanisms [12] . In a murine model of CGVHD after myeloablative transplantation, there have been reports of antibodies against nephrin causing severe immune complex glomerulonephritis [13, 14] . CGVHD in humans sometimes shares clinical manifestations with various autoimmune diseases [15] .
Huang et al [16] reported anti-PLA2R autoantibodies on 5 patients with post-allo-HSCT MN. Anti-PLA2R autoantibodies were negative in 4 patients, whereas serum from 1 patient was reactive with PLA2R.
Chan et al [8] reported the clinical courses of 4 patients with post-HSCT MGN. Three of the 4 patients were followed up for a mean period of 29.3 months and were treated with PSL, angiotensin-converting enzyme inhibitor, mycophenolate mofetil, or CyA. Two patients achieved CR, but 1 patient developed renal impairment. Reddy et al [9] reported that all 5 of their patients showed improvement of proteinuria, whereas the 2 patients receiving initial treatment with rituximab had an excellent response. Terrier et al [10] reported that 75% of their patients achieved partial or CR with PSL and CyA therapy. Regarding the long-term outcome, Kemper et al [17] reported survival with continuous remission of proteinuria in patients with post-HSCT MGN at 96 months after ceasing treatment of MGN, and Cupelli et al [18] reported the same outcome after 60 months.
Because isolated staining for IgG4 with positive staining for C3 and positivity for anti-PLA2R autoantibody are considered to be the characteristics of idiopathic MGN [3] , our first 4 cases may be consistent with secondary MGN because they showed predominant IgG1 and IgG4 staining with negative C3 staining. On the other hand, our last case indicates that other types of HSCT-related nephropathy with membranoproliferative glomerulonephritis-like lesions can also occur.
In conclusion, we found that HSCT-related MGN is developed only after using UCBT, but is not developed after using unrelated BMT. Although previous reports did not differentiate the 2 methods, the presence of HLA antibodies against the UCB units may be a causative factor of MGN.
The pathogenesis of close relation between UCBT and MGN will be solved. There were 2 morphologic patterns: early MGN and membranoproliferative pattern glomerulonephritis. Because PLA2R in 3 cases was all negative, this nephropathy may be consistent with secondary MGN. MGN was developed 2 to 15 months after CGVHD onset on 5 cases, and in 2 cases with recurrence of this nephropathy, extrarenal symptoms of GVHD coexisted. This will show a close relation considered between CGVHD and MGN. 
